Imiglucerase

DB00053ApprovedInvestigationalProtein Based TherapiesHydrolytic Lysosomal Glucocerebroside-specific Enzyme

Imiglucerase is a form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD.

Mechanism: Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.
Curator reviewed
Primary indication: For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)Curator reviewed · 2 structured indications
Formula / weight: C₂₅₃₂H₃₈₅₄N₆₇₂O₇₁₁S₁₆ · 55597.4 Da
First approval: Canada, 2004 · United States, 1994 · European Union, 2020
Code names: ISU-302
Brand names: Cerezyme

Resolves to

Compound

UNIIQ6U6J48BWYCAS154248-97-2ChEMBLCHEMBL1201632KEGGD02810

Clinical / RWD

RxNorm84959ATCA16AB02PharmGKBPA164742934

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

19Marketed productsAcross 10 countries and 7 labellers

1ATC codeIncluding every combination product, plus 9 drug categories

2+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Imiglucerase, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account